Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study

Future Oncology
Jason J LukeBruce A Feinberg

Abstract

Targeted therapy (TT) and immuno-oncology (IO) drugs are approved for patients with BRAF mutant metastatic melanoma (MM). We compared real-world outcomes for first-line (1L) TT versus 1L IO to evaluate optimal sequencing. Physicians-identified BRAF mutant MM patients initiating 1L TT or IO therapies and extracted treatment, disease and clinical outcomes including disease response which were compared between TT and IO and individual regimens. 440 MM patients (TT = 283, IO = 157) were identified. A higher proportion of TT patients had liver metastases (46.3 vs 35.0%) and abnormal lactate dehydrogenase (61.1 vs 42.7%). IO-treated had a RECIST-determined response rate of 45.9 versus 60.1% for TT and time on treatment of 7.2 versus 11.4 months, respectively. There was no survival difference between cohorts. Despite higher risk patients, 1L TT resulted in higher response rate and longer treatment duration suggesting a preferred 1L sequence.

References

Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Sep 30, 2014·The New England Journal of Medicine·James LarkinAntoni Ribas
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertDirk Schadendorf
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Nov 16, 2016·Journal of Immunotherapy·Douglas B JohnsonRyan J Sullivan
Sep 12, 2017·The New England Journal of Medicine·Jedd D WolchokJames Larkin
Sep 30, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·B SassolasC Bédane
Apr 19, 2018·Journal of Translational Medicine·Paolo A AsciertoIgor Puzanov
Aug 11, 2018·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Matteo S CarlinoAdil Daud
Jan 4, 2019·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Marco DoniaInge Marie Svane
Jan 12, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Inês Pires da SilvaAlexander M Menzies

❮ Previous
Next ❯

Citations

Jan 7, 2020·Expert Review of Anticancer Therapy·Dimitrios C ZiogasHelen Gogas
Jul 12, 2020·The British Journal of Dermatology·X Bai, K T Flaherty
Feb 15, 2020·Advances in Therapy·Sandra D GriffithRebecca A Miksad
Feb 15, 2020·Advances in Therapy·Ajeet Gajra, Bruce A Feinberg
Oct 18, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gabriela MarsavelaElin S Gray
Oct 14, 2020·The Journal of Investigative Dermatology·Florence PoizeauAlain Dupuy

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02224781

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Nature Reviews. Drug Discovery
Alexandra Flemming
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
C Hafner
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Leora HornBruce E Johnson
© 2022 Meta ULC. All rights reserved